



CAMSING HEALTHCARE LIMITED

(Company Registration No. 197903888Z)
(Incorporated in the Republic of Singapore)

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED 31 OCTOBER 2023

Note:

Pursuant to a notice of compliance issued by Singapore Exchange Regulation dated 6 February 2020, Camsing Healthcare Limited is required, under Rule 705(2C) of the Mainboard Rules of the Singapore Exchange Securities Trading Limited, to perform quarterly reporting of financial results.

CAMSING HEALTHCARE LIMITED

Contents

	Page
Condensed Interim Consolidated Statement Comprehensive Income	3
Condensed Interim Statements of Financial Position	5
Condensed Interim Consolidated Statement of Changes in Equity	7
Condensed Interim Consolidated Statement of Cash Flows	9
Notes to the Condensed Interim Financial Statements	10
Other Information Required by Listing Rules Appendix 7.2	22

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE NINE MONTHS ENDED 31 OCTOBER 2023**

		3 Months Ended 31 Oct 2023 S\$'000	3 Months Ended 31 Oct 2022 S\$'000	Change % +/-	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000	Change % +/-
	Note						
Revenue	5	1,371	1,729	(21%)	4,185	4,475	(6%)
Cost of sales		(575)	(752)	(24%)	(1,750)	(1,969)	(11%)
Gross profit		<u>796</u>	<u>977</u>	(19%)	<u>2,435</u>	<u>2,506</u>	(3%)
Other income		18	22	(18%)	81	128	(37%)
Marketing and distribution expenses		(1,063)	(1,059)	N.M.	(2,888)	(2,993)	(4%)
Administrative and other operating expenses		(208)	(404)	(49%)	(808)	(861)	(6%)
Finance costs		(141)	(136)	4%	(423)	(342)	24%
Loss before tax	7	<u>(598)</u>	<u>(600)</u>	N.M.	<u>(1,603)</u>	<u>(1,562)</u>	3%
Income tax expense		-	-	-	-	-	-
Loss for the period		<u><u>(598)</u></u>	<u><u>(600)</u></u>	N.M.	<u><u>(1,603)</u></u>	<u><u>(1,562)</u></u>	3%
Other comprehensive income:							
<i>Items that may be reclassified subsequently to profit or loss</i>							
Foreign currency translation		<u>1</u>	<u>-</u>	N.M.	<u>1</u>	<u>-</u>	N.M.
Other comprehensive income, net of tax		<u>1</u>	<u>-</u>	N.M.	<u>1</u>	<u>-</u>	N.M.
Total comprehensive loss for the period		<u><u>(597)</u></u>	<u><u>(600)</u></u>	(1%)	<u><u>(1,602)</u></u>	<u><u>(1,562)</u></u>	3%

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE NINE MONTHS ENDED 31 OCTOBER 2023 (cont'd)**

	3 Months Ended 31 Oct 2023 S\$'000	3 Months Ended 31 Oct 2022 S\$'000	Change % +/-	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000	Change % +/-
Note						
Loss attributable to:						
Owners of the Company	(597)	(600)	(1%)	(1,602)	(1,562)	3%
Non-controlling interest	(1)	-	N.M.	(1)	-	N.M.
	<u>(598)</u>	<u>(600)</u>	N.M.	<u>(1,603)</u>	<u>(1,562)</u>	3%
Total comprehensive loss attributable to:						
Owners of the Company	(596)	(600)	(1%)	(1,601)	(1,562)	2%
Non-controlling interest	(1)	-	N.M.	(1)	-	N.M.
	<u>(597)</u>	<u>(600)</u>	(1%)	<u>(1,602)</u>	<u>(1,562)</u>	3%

N.M.: Not meaningful

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
AS AT 31 OCTOBER 2023**

	Note	Group		Company	
		31 Oct 2023 S\$'000	31 Jan 2023 S\$'000	31 Oct 2023 S\$'000	31 Jan 2023 S\$'000
ASSETS					
Non-current assets					
Plant and equipment	11	82	141	-	-
Right-of-use assets	12	1,609	1,837	-	-
Investment in subsidiaries		-	-	900	900
Other receivables	14	245	315	-	-
		<u>1,936</u>	<u>2,293</u>	<u>900</u>	<u>900</u>
Current assets					
Cash and bank balances		107	437	1	204
Trade receivables	14	82	134	-	-
Other receivables, deposits and prepayments	14	347	423	45	27
Inventories	13	562	919	-	-
		<u>1,098</u>	<u>1,913</u>	<u>46</u>	<u>231</u>
TOTAL ASSETS		<u>3,034</u>	<u>4,206</u>	<u>946</u>	<u>1,131</u>
Current liabilities					
Trade payables	16	881	813	-	-
Other payables and accruals	16	1,937	1,954	1,066	469
Borrowings	15	5,489	4,697	4,303	3,987
Lease liabilities	17	1,206	1,142	-	-
Provisions		20	30	-	-
Contract liabilities	5	110	217	-	-
		<u>9,643</u>	<u>8,853</u>	<u>5,369</u>	<u>4,456</u>
Non-current liabilities					
Lease liabilities	17	545	904	-	-
Provisions		184	185	-	-
		<u>729</u>	<u>1,089</u>	<u>-</u>	<u>-</u>
TOTAL LIABILITIES		<u>10,372</u>	<u>9,942</u>	<u>5,369</u>	<u>4,456</u>
NET LIABILITIES		<u>(7,338)</u>	<u>(5,736)</u>	<u>(4,423)</u>	<u>(3,325)</u>

CAMSING HEALTHCARE LIMITED**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
AS AT 31 OCTOBER 2023 (cont'd)**

		Group		Company	
	Note	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
		S\$'000	S\$'000	S\$'000	S\$'000
EQUITY					
Capital and reserves attributable to equity holders of the Company					
Share capital	18	14,250	14,250	14,250	14,250
Foreign currency translation deficit		(3)	(4)	-	-
Accumulated losses		(21,584)	(19,982)	(18,673)	(17,575)
Equity attributable to owners of the Company		(7,337)	(5,736)	(4,423)	(3,325)
Non-controlling interests		(1)	-	-	-
NET DEFICIT		(7,338)	(5,736)	(4,423)	(3,325)

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE NINE MONTHS ENDED 31 OCTOBER 2023**

Group	Share capital S\$'000	Foreign currency translation reserve S\$'000	Accumulated losses S\$'000	Equity attributable to owners of the Company S\$'000	Non- controlling interest S\$'000	Total S\$'000
Balance at 1 February 2022	14,250	(4)	(17,577)	(3,331)	(3)	(3,334)
Loss for the period, representing total comprehensive loss for the period	-	-	(962)	(962)	-	(962)
Balance at 31 July 2022	14,250	(4)	(18,539)	(4,293)	(3)	(4,296)
Loss for the period, representing total comprehensive loss for the period	-	-	(600)	(600)	-	(600)
Balance at 31 October 2022	14,250	(4)	(19,139)	(4,893)	(3)	(4,896)
Balance at 1 February 2023	14,250	(4)	(19,982)	(5,736)	-	(5,736)
Loss for the period, representing total comprehensive loss for the period	-	-	(1,005)	(1,005)	-	(1,005)
Balance at 31 July 2023	14,250	(4)	(20,987)	(6,741)	-	(6,741)
Loss for the period, representing total comprehensive loss for the period	-	1	(597)	(596)	(1)	(597)
Balance at 31 October 2023	14,250	(3)	(21,584)	(7,337)	(1)	(7,338)

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE NINE MONTHS ENDED 31 OCTOBER 2023 (cont'd)**

Company	Share capital S\$'000	Accumulated losses S\$'000	Total S\$'000
Balance at 1 February 2022	14,250	(14,166)	84
Loss for the period, representing total comprehensive loss for the period	-	(261)	(261)
Balance at 31 July 2022	14,250	(14,427)	(177)
Loss for the period, representing total comprehensive loss for the period	-	(431)	(431)
Balance at 31 October 2022	14,250	(14,858)	(608)
Balance at 1 February 2023	14,250	(17,575)	(3,325)
Loss for the period, representing total comprehensive loss for the period	-	(746)	(746)
Balance at 31 July 2023	14,250	(18,321)	(4,071)
Loss for the period, representing total comprehensive loss for the period	-	(352)	(352)
Balance at 31 October 2023	14,250	(18,673)	(4,423)

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED 31 OCTOBER 2023**

	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000
Operating activities:		
Loss before tax	(1,603)	(1,562)
Adjustments for:		
Depreciation for plant and equipment	63	66
Depreciation for right-of-use assets	949	982
Plant and equipment written off	-	1
Inventory written off	3	2
Gain on lease modification	-	(2)
Interest expense	423	342
Operating cash flows before changes in working capital	(165)	(171)
Trade and other receivables	198	(600)
Inventories	354	(8)
Trade and other payables	52	(681)
Contract liabilities	(107)	429
Provisions	(10)	19
Cash generated from / (used in) operations	322	(1,012)
Income tax	-	-
Net cash flows generated from / (used in) operating activities	322	(1,012)
Investing activities:		
Purchase of plant and equipment	(4)	(152)
Net cash flows used in investing activities	(4)	(152)
Financing activities:		
Interest paid	(81)	(97)
Repayment of bank loan	(295)	(360)
Repayment of lease liabilities	(1,017)	(1,088)
Loan from ultimate holding company	545	-
Loan from QRH	-	2,532
Loan from third-party lenders	200	200
Net cash flows (used in) / from financing activities	(648)	1,187
Net (decrease)/increase in cash and cash equivalents	(330)	23
Cash and cash equivalents at beginning of financial period	437	474
Cash and cash equivalents at end of financial period	107	497

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

1 GENERAL INFORMATION

Camsing Healthcare Limited (the “Company” and together with its subsidiaries, the “Group”) is a limited liability company domiciled and incorporated in Singapore and is listed on the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The address of the Company's registered office is at 16 Raffles Quay #17-03 Hong Leong Building, Singapore 048581. The address of its principal place of business is 10 Kaki Bukit Ave 1 #04-05 Kaki Bukit Industrial Park Singapore 417942. The principal activity of the Company is that of investment holding. The principal activity of its principal subsidiary, Nature’s Farm Pte Ltd (“NF”), is trading in health foods and supplements.

2 BASIS OF PREPARATION

The condensed interim financial statements for the three months ended 31 October 2023 are prepared in accordance with the historical cost convention, except as disclosed in the accounting policies below and are drawn up in accordance with the Singapore Financial Reporting Standards (International) (“SFRS(I)”) – 34 *Interim Financial Reporting*. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the change in the Group’s financial position and performance of the Group since the last annual financial statements for the financial year ended 31 January 2023. The financial statements are presented in Singapore dollars (“S\$”) and all values are rounded to the nearest thousand (S\$’000) as indicated.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I), except for the adoption of new and revised standards as set out below.

2.1 Adoption of New and Revised Standards

In the current financial period, the Group has adopted the new and revised SFRS(I) and Interpretations of SFRS(I) (“SFRS(I) INT”) that are relevant to its operations and effective for the current financial period. Changes to the Group’s accounting policies have been made as required, in accordance with the transitional provisions in the respective SFRS(I) and SFRS(I) INT. The adoption of these new and revised SFRS(I) and SFRS(I) INT did not result in substantial changes to the Group’s and Company’s accounting policies and had no material effect on the financial results or position.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

2 BASIS OF PREPARATION (cont'd)

2.2 Fundamental Accounting Concept (cont'd)

The Group incurred a net loss of S\$1,602,000 (31 October 2022: S\$1,562,000) for the financial period ended 31 October 2023 and was in net deficit position of S\$7,338,000 (31 Jan 2023: S\$5,736,000) as at 31 October 2023. In addition, the Group had cash and bank balances of S\$107,000 (31 Jan 2023: S\$437,000) and borrowings of S\$5,489,000 (31 Jan 2023: S\$4,697,000) as at 31 October 2023.

The facts and circumstances above indicate the existence of material uncertainties that may cast significant doubts over the abilities of the Group and the Company to continue as going concerns. Notwithstanding this, the accompanying financial statements have been prepared on a going concern basis on the following grounds:

- (i) An amount of S\$5,100,000 is, as of the date of the financial statements, held in escrow as a proof of funds for the purpose of investment into the Company by investors (“Potential Investor(s)”) to be released to the Company, subject to the satisfaction of certain conditions, including the completion of discussions and the resumption of trading of the Company’s shares on SGX-ST (the “**New Investment**”). Shortly after the release of the amount of S\$5,100,000 to the Company, the Company plans to utilise approximately S\$3,230,000 to discharge the outstanding principal amount owing to Qiren Holdings Pte. Ltd. (“**QRH**”) under the loan agreements as set out in Note 15. Shareholders may refer to the Company’s announcement regarding the entry into the New Investment released via SGXNet on 14 June 2023 (as well as any other subsequent update announcements) for more information.
- (ii) The major shareholder (ultimate holding company) has undertaken to provide financial support at the request of management.
- (iii) As disclosed in Note 15 to the financial statements, a subsidiary of the Group has outstanding bank loan of S\$89,000 and has breached certain bank covenants and defaulted on the repayment of the bank loan since 2019. The Group has been making monthly repayments of to the bank. As at 31 October 2023, the Group has not received any notice from the bank for immediate repayment and shall continue with the monthly repayments until January 2024.
- (iv) The principal subsidiary, Nature’s Farm Pte Ltd, would generate sufficient cash flows in the next 12 months from its operations to enable it to continue as a going concern.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

3 CRITICAL ACCOUNTING ESTIMATES, ASSUMPTIONS AND JUDGEMENTS

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 January 2023.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

4 SEASONAL OPERATIONS

The Group's businesses were not affected significantly by seasonal or cyclical factors during the financial period.

5 REVENUE

(i) Disaggregation of revenue from contracts with customers

The Company derives revenue from contracts with customers through the transfer of goods at a point in time and these pertain to retail revenue derived in Singapore.

	3 Months Ended 31 Oct 2023 S\$'000	3 Months Ended 31 Oct 2022 S\$'000	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000
<u>Sales of health foods and supplements</u>				
Retail and online	1,264	1,704	3,731	4,388
Corporate sales	98	-	430	-
Consignment income	9	25	24	87
	<u>1,371</u>	<u>1,729</u>	<u>4,185</u>	<u>4,475</u>

(ii) Contract liabilities

Information about contract liabilities from contracts with customers disclosed as below:

	31 Oct 2023 S\$'000	31 Jan 2023 S\$'000
Group		
Customer loyalty programme – unredeemed loyalty points	110	110
Corporate sales – undelivered redemption code	-	107
	<u>110</u>	<u>217</u>

Contract liabilities primarily pertain to redeemable points accorded to customers from their purchases with the Group under the Group's customer loyalty programme and advance payment received from customers for sale of products.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

6 SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services, and has three reportable operating segments as follows:

- 1) Retail and Online Sales includes consignment sales, trading and distribution sales in health foods and supplements.
- 2) Corporate Sales includes business-to-business sales in health foods and supplements.
- 3) Head Office includes general corporate income and expense items.

Business Segments	Retail and Online Sales		Corporate Sales		Head Office		Consolidated		
	3 Months Ended 31 Oct 2023	3 Months Ended 31 Oct 2022	3 Months Ended 31 Oct 2023	3 Months Ended 31 Oct 2022	3 Months Ended 31 Oct 2023	3 Months Ended 31 Oct 2022	3 Months Ended 31 Oct 2023	3 Months Ended 31 Oct 2022	
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	
	Revenue:								
	External customers	1,273	1,729	98	-	-	-	1,371	1,729
Results:									
Depreciation of plant and equipment	(19)	(26)	-	-	-	-	(19)	(26)	
Depreciation for right-of-use assets	(326)	(336)	-	-	-	-	(326)	(336)	
Plant and equipment written off	-	(1)	-	-	-	-	-	(1)	
Interest expenses	(35)	(38)	-	-	(106)	(98)	(141)	(136)	
Loss before tax	(198)	(101)	(44)	-	(356)	(499)	(598)	(600)	

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

6. SEGMENT INFORMATION (Cont'd)

Business Segments	Retail and Online Sales		Corporate Sales		Head Office		Consolidated	
	9 Months Ended 31 Oct 2023	9 Months Ended 31 Oct 2022	9 Months Ended 31 Oct 2023	9 Months Ended 31 Oct 2022	9 Months Ended 31 Oct 2023	9 Months Ended 31 Oct 2022	9 Months Ended 31 Oct 2023	9 Months Ended 31 Oct 2022
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue:								
External customers	3,755	4,475	430	-	-	-	4,185	4,475
Results:								
Depreciation of plant and equipment	(63)	(66)	-	-	-	-	(63)	(66)
Depreciation for right-of-use assets	(949)	(982)	-	-	-	-	(949)	(982)
Plant and equipment written off	-	(1)	-	-	-	-	-	(1)
Inventory written off	(3)	(2)	-	-	-	-	(3)	(2)
Interest expenses	(108)	(108)	-	-	(315)	(234)	(423)	(342)
Loss before tax	(321)	(834)	(165)	-	(1,117)	(728)	(1,603)	(1,562)
	31 Oct 2023	31 Oct 2022	31 Oct 2023	31 Oct 2022	31 Oct 2023	31 Oct 2022	31 Oct 2023	31 Oct 2022
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Assets:								
Segment assets	2,990	4,250	-	-	44	446	3,034	4,696
Segment liabilities	4,479	4,751	-	-	5,893	4,841	10,372	9,592

Geographical information

The Group's revenue and non-current assets are entirely based in Singapore.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

7 LOSS BEFORE TAX

The following items have been included in arriving at the loss for the period:

	3 Months Ended 31 Oct 2023 S\$'000	3 Months Ended 31 Oct 2022 S\$'000	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000
Employee benefits expense	570	457	1,429	1,373
Depreciation for plant and equipment	19	26	63	66
Depreciation for right-of-use assets	326	336	949	982
Lease expenses not included in lease liabilities:				
- Variable lease expenses	14	7	37	37
- Operating lease expenses	24	15	69	34
Plant and equipment written off	-	1	-	1
Inventories written off	-	-	3	2
Interest expenses	141	136	423	342
Gain on lease modification	-	(2)	-	(2)
Government grant income	(6)	(4)	(34)	(16)

8. RELATED PARTY TRANSACTIONS

Some of the Company's transactions and arrangements are with related parties and the effect of these on the basis determined between the parties is reflected in these financial statements. The balances are unsecured, interest-free and repayable on demand.

	3 Months Ended 31 Oct 2023 S\$'000	3 Months Ended 31 Oct 2022 S\$'000	9 Months Ended 31 Oct 2023 S\$'000	9 Months Ended 31 Oct 2022 S\$'000
Compensation of key management personnel				
- Director of the Company	107	49	236	124
- Director of a subsidiary	-	32	-	108
- Other key management personnel	32	-	98	-
Interest on loan from controlling shareholder	9	4	20	11
Loan from ultimate holding company	275	-	545	-

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

9 LOSS PER SHARE

Loss per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

	3 Months Ended 31 Oct 2023	3 Months Ended 31 Oct 2022	9 Months Ended 31 Oct 2023	9 Months Ended 31 Oct 2022
Loss per share (in SGD cents)				
- Basic ⁽¹⁾	(1.99)	(2.00)	(5.34)	(5.21)
- Fully diluted ⁽²⁾	(1.99)	(2.00)	(5.34)	(5.21)

⁽¹⁾ Basic (loss) /earnings per share (“EPS”) is calculated on the Group’s loss for the period divided by the weighted average number of ordinary shares in issue during the reporting period of 29,999,993 shares (31 Oct 2022: 29,999,993 shares).

⁽²⁾ As there are no dilutive potential ordinary shares issued and/or granted, the fully diluted EPS is the same as the basic EPS.

10 FINANCIAL INSTRUMENTS

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	S\$’000	S\$’000	S\$’000	S\$’000
Financial assets at amortised cost	661	1,043	3	206
Financial liabilities at amortised cost	10,058	9,510	5,369	4,456

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

11 PROPERTY, PLANT AND EQUIPMENT

Group	Plant and Machinery, Furniture and Vehicles S\$'000
Cost	
As at 1 Feb 2022	1,988
Additions	153
Disposal/written off	(109)
As at 31 Jan 2023	<u>2,032</u>
As at 1 Feb 2023	2,032
Additions	4
As at 31 Oct 2023	<u>2,036</u>
Accumulated depreciation	
As at 1 Feb 2022	1,749
Depreciation charge for the year	93
Disposal/written off	(109)
As at 31 Jan 2023	<u>1,733</u>
As at 1 Feb 2023	1,733
Depreciation charge for the year	63
As at 31 Oct 2023	<u>1,796</u>
Accumulated impairment loss	
As at 1 Feb 2022	133
Impairment loss	25
As at 31 Jan 2023	<u>158</u>
As at 1 Feb 2023	158
Impairment loss	-
As at 31 Oct 2023	<u>158</u>
Net carrying amount	
As at 31 Jan 2023	<u>141</u>
As at 31 Oct 2023	<u>82</u>

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

12 RIGHT-OF-USE ASSETS

Group	Office Premise and Retail Outlets S\$'000
Cost	
As at 1 Feb 2022	6,785
Additions	1,074
Lease modification	388
Early termination	(208)
Expiry	(629)
As at 31 Jan 2023	<u>7,410</u>
As at 1 Feb 2023	7,410
Additions	721
As at 31 Oct 2023	<u>8,131</u>
Accumulated depreciation and impairment loss	
As at 1 Feb 2022	5,169
Depreciation charge for the period	1,295
Reversal of impairment loss	(63)
Early termination	(199)
Expiry	(629)
As at 31 Jan 2023	<u>5,573</u>
As at 1 Feb 2023	5,573
Depreciation charge for the period	949
As at 31 Oct 2023	<u>6,522</u>
Net carrying amount	
As at 31 Jan 2023	<u>1,837</u>
As at 31 Oct 2023	<u>1,609</u>

13 INVENTORIES

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	S\$'000	S\$'000	S\$'000	S\$'000
Health foods and supplements:				
Raw materials	182	379	-	-
Finished goods	380	535	-	-
Goods in transit	-	5	-	-
	<u>562</u>	<u>919</u>	<u>-</u>	<u>-</u>

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

14 TRADE AND OTHER RECEIVABLES

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Non-current</u>				
- Rental deposits	238	301	-	-
- Deferred lease payments	7	14	-	-
	<u>245</u>	<u>315</u>	<u>-</u>	<u>-</u>
<u>Current</u>				
Trade receivables	82	134	-	-
			-	-
Other receivables, deposits and prepayments:				
- Advance payment to suppliers	31	203	-	-
- Rental deposits	234	128	-	-
- Deferred lease payments	18	17	-	-
- Prepayments	64	32	43	25
- Amount due from subsidiaries	-	-	2	2
- Sundry receivables	723	825	59	59
	<u>1,070</u>	<u>1,205</u>	<u>104</u>	<u>86</u>
Impairment loss allowance on sundry receivables	(723)	(782)	(59)	(59)
	<u>347</u>	<u>423</u>	<u>45</u>	<u>27</u>

15 BORROWINGS

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Bank loan ⁽¹⁾	89	384	-	-
Loan from the ultimate holding company ⁽²⁾	891	326	-	-
Loans from QRH ⁽³⁾	3,871	3,579	3,871	3,579
Loans from third-party lenders ⁽⁴⁾	638	408	432	408
	<u>5,489</u>	<u>4,697</u>	<u>4,303</u>	<u>3,987</u>

⁽¹⁾ As at 31 October 2023, the Group has an outstanding bank loan of S\$89,000 (31 Jan 2023: S\$384,000) bearing interest rates between 1.56% and 2.71% per annum.

⁽²⁾ Loan from the ultimate holding company are unsecured, bears interest at 5% per annum and is repayable from Apr 2024 to Aug 2024.

⁽³⁾ Loans from QRH is for the Group's working capital, bears interest of 12% per annum. On 3 March 2022, the Company and QRH entered into an investment agreement in connection with the redemption of the outstanding loans to subscribe for 102,166,007 shares of the Company, at an issue price of S\$0.042 each, and 167,834,000 share options at an aggregate price of S\$1, which shall be set-off against the outstanding loans owing to QRH and any remaining consideration shall be paid in cash to the Company, subject to certain conditions being fulfilled by the Company, which includes the resumption of trading of the Company's shares on SGX-ST by the long-stop date, 23 December 2023.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

(4) In September 2022, the Company entered into 2 loan agreements with third-party lenders to obtain working capital loans of S\$200,000 each at an interest of 8% per annum, with corporate guarantees granted by the Company’s principal subsidiary, Nature’s Farm Pte Ltd (“NF”). The outstanding principal amount of the respective loans and the respective interest accrued are repayable, in a single repayment, 12 months from the respective drawdown dates of each loan in October and November 2023, failing which, a default interest of 12% per annum shall be charged on unpaid amounts from the date of default until the date of full settlement. The Company had subsequently entered into extension letters with the respective third-party lenders, which provided, *inter alia*, that the repayment date for both loans (including the interest accrued) are now extended to 31 March 2024.

In February 2023, NF entered into a facility agreement with a third party lender to obtain a facility of up to S\$200,000 (the “Facility Agreement”) for the purpose of purchasing certain products to be sold by NF, which was specified and designated as “Specified Products” in the Facility Agreement. The facility may be drawn down as advances (each, an “Advance”) as long as the aggregate of such Advances do not exceed S\$200,000 at any point in time, and each Advance will bear interest of 8% per annum, and a default interest of 12% per annum from the date of default until the date of full settlement of the unpaid sum. Pursuant to the Facility Agreement, NF assigns 15% of the receivables arising from or in connection with the sale of Specified Products purchased utilising an Advance. All outstanding amounts (which includes the aggregate principal amount of all Advances outstanding, and interest accrued) are to be paid as a single repayment on the Final Repayment Date (as defined in the Facility Agreement), prior to the termination date of 6 months from the date of the Facility Agreement. As of 30 April 2023, the facility has been fully drawn down. NF had subsequently entered into an extension letter with the third-party lender, which provided, *inter alia*, that the repayment date for the facility (including the outstanding principal amount and interest accrued) is now extended to 29 February 2023.

16 TRADE AND OTHER PAYABLES

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	S\$’000	S\$’000	S\$’000	S\$’000
<u>Current</u>				
Trade payables	881	813	-	-
Other payables and accruals				
- Third parties	999	723	569	347
- Amount due to subsidiary	-	-	246	-
- Accrued operating expenses	938	908	251	122
- Accrued marketing expenses	-	323	-	-
	1,937	1,954	1,066	469

Included in trade payables and accrued expenses are balances owing to I-Nitra Consulting Limited (“I-Nitra”) of S\$431,000 (31 Jan 2023: S\$413,000) and S\$149,000 (31 Jan 2023: S\$149,000) respectively. The outstanding balance is attributable to the purchase of some honey products from I-Nitra that were previously sold by NF to another party as well as amounts due to I-Nitra pursuant to consignment arrangements between I-Nitra (as consignor) and NF (as consignee) upon the sale of the consigned goods by the latter. The purchase transactions and consignment arrangements ostensibly took place during 2019 on the previous management’s watch and were subject matter of investigation by the special auditors pursuant to a notice of compliance issued by the Singapore Exchange Regulation in March 2019. While these transactions involving I-Nitra were at first blush redolent of round-tripping, the special auditors had emphatically concluded that they “did not find any conclusive evidence of round-tripping”. Accordingly, and out of accounting prudence, the incumbent management has not derecognised the liability as at reporting date.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

17 LEASE LIABILITIES

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2022
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Lease liabilities	1,206	1,142	-	-
<u>Non-current</u>				
Lease liabilities	545	904	-	-
Total lease liabilities	<u>1,751</u>	<u>2,046</u>	<u>-</u>	<u>-</u>

The Group have entered into lease agreement for retail outlets. These non-cancellable leases have lease terms of between 1 and 3 years. The effective interest rate of lease liabilities is 5.25%.

18 SHARE CAPITAL

	Group and Company			
	31 Oct 2023		31 Jan 2023	
	Number of		Number of	
	ordinary	S\$'000	ordinary	S\$'000
	shares		shares	
<u>Issued and fully paid:</u>				
At beginning and end of period/year	<u>29,999,993</u>	<u>14,250</u>	<u>29,999,993</u>	<u>14,250</u>

The Company has one class of ordinary shares which carry one vote per share. The ordinary shares have no par value and carry a right to dividends as and when declared by the Company.

19 NET LIABILITIES VALUE

Net liabilities value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the (a) currently period reported on and (b) immediately preceding financial year

	Group		Company	
	31 Oct 2023	31 Jan 2023	31 Oct 2023	31 Jan 2023
	Cents	Cents	Cents	Cents
Net liabilities per ordinary share based on existing issued share capital as at the end of period/year	<u>24.46</u>	<u>19.12</u>	<u>14.74</u>	<u>11.08</u>

Net liability value per ordinary share was based on 29,999,993 (31 Jan 2023: 29,999,993) ordinary shares outstanding as at end of the reporting period.

20 SUBSEQUENT EVENTS

There are no known significant subsequent events which have led to adjustment to this set of interim financial statements.

OTHER INFORMATION REQUIRED BY LISTING RULES APPENDIX 7.2

21A Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

There have been no changes in the Company's share capital since the end of the previous period reported.

For the avoidance of doubt, the Company has no outstanding convertible securities as at: (i) the end of the current financial period reported on; and (ii) the corresponding period of the immediately preceding financial year.

21B The total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

	31 Oct 2023	31 Jan 2023
	Number of	Number of
	ordinary shares	ordinary shares
Number of issued shares	<u>29,999,993</u>	<u>29,999,993</u>

21C A statement showing all sales, transfers, disposals, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

The Company does not have any treasury shares.

22 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by the auditors.

23 Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).

Not applicable.

CAMSING HEALTHCARE LIMITED

24 Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:-

- (a) Updates on the efforts taken to resolve each outstanding audit issue**
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed**

Please refer to the FY2023 First Quarter Results announced on 28 September 2022 for details on efforts taken to resolve outstanding audit issues.

The Board confirms that the impact of all outstanding audit issues on this Announcement have been adequately disclosed herein.

25 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the revenue, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets and liabilities of the group during current financial period reported on.

Review of Results

Q3FY2024 vs Q3FY2023

The Group's revenue of S\$1,371,000 for the three months ended 31 October 2023 ("Q3FY2024") were generated from local retail and corporate sales. The decrease in the revenue by S\$358,000 compared to the three months ended 31 October 2022 ("Q3FY2023") was mainly due to reduced demand for products during the period under review.

The gross margin increased from 57% in Q3FY2023 to 58% in Q3FY2024 mainly due to product mix.

The Group recorded other income of S\$18,000 in Q3FY2024, compared to S\$22,000 in Q3FY2023. The decrease is mainly due to lower product display fee in Q3FY2024.

Marketing and distribution expenses increased marginally by S\$4,000 from S\$1,059,000 in Q3FY2023 to S\$1,063,000 in Q3FY2024. The increase was mainly due to higher staff and payroll costs, partly offset by decrease in advertisement, promotion and campaign expenses.

Administrative and other operating expenses decreased by S\$196,000 or 49% from S\$404,000 in Q3FY2023 to S\$208,000 in Q3FY2024, primarily due to lower professional fees incurred in Q3FY2024.

The higher finance costs were due mainly to the higher outstanding borrowing in Q3FY2024.

The Group recorded a loss before tax of S\$598,000 in Q3FY2024 compared to a loss before tax of S\$600,000 in Q3FY2023, which was mainly attributable to lower general and administrative operating expenses, partly offset by lesser revenue generated during the period under review.

CAMSING HEALTHCARE LIMITED

9MFY2024 vs 9MFY2023

The Group's revenue of S\$4,185,000 for the nine months ended 31 October 2023 ("9MFY2024") were generated from local retail and corporate sales. The decrease in the revenue by S\$290,000 or 6% compared to the nine months ended 31 October 2022 ("9MFY2023") was mainly due to reduced demand for products during the period under review.

The gross margin increased from 56% in 9MFY2023 to 58% in 9MFY2024 mainly due to product mix.

The Group recorded other income of S\$81,000 in 9MFY2024, compared to S\$128,000 in 9MFY2023. The decrease is mainly due to the absence of rental rebate and lower product display fee in 9MFY2024.

Marketing and distribution expenses decreased by S\$105,000 or 4% from S\$2,993,000 in 9MFY2023 to S\$2,888,000 in 9MFY2024. The decrease was mainly due to decrease in advertisement, promotion and campaign expenses.

Administrative and other operating expenses decreased by S\$53,000 or 6% from S\$861,000 in 9MFY2023 to S\$808,000 in 9MFY2024, primarily due to lower professional fees incurred in Q3FY2024.

The higher finance costs were mainly due to higher outstanding borrowing in 3MFY2024.

The Group recorded a loss before tax of S\$1,603,000 in 9MFY2024 compared to a loss before tax of S\$1,562,000 in 9MFY2023, which was mainly attributable to lower revenue, higher finance costs, and lower other income, partly offset by lower marketing and distribution expenses, and lower general and administrative operating expenses during the period under review.

Review of Statement of Financial Position

The Group's non-current assets stood at S\$1,936,000 as of 31 October 2023, compared to S\$2,293,000 as of 31 January 2023, and comprised plant and equipment, right-of-use assets and other receivables. The decrease of S\$357,000 was mainly attributable to the decrease in plant and equipment, and right-of-use assets as a result of depreciation, and the decrease in non-current portion of the rental deposits during the period under review.

The current assets stood at S\$1,098,000 as of 31 October 2023, compared to S\$1,913,000 as of 31 January 2023. Overall, the decrease was mainly due to the decrease in inventories, cash and bank balances, other receivables deposits and prepayments, and trade receivables.

The current liabilities stood at S\$9,643,000 as of 31 October 2023, compared to S\$8,853,000 as of 31 January 2023. The net increase of S\$790,000 in current liabilities was mainly due to increase in borrowings, trade payables, and lease liabilities, partly offset by decrease in contract liabilities, other payables and accruals, and provisions during the period under review.

The decrease of S\$360,000 in non-current liabilities was mainly due to re-classification of lease liability from non-current to current.

Overall, the Group's net liabilities stood at S\$7,338,000 as of 31 October 2023, compared to S\$5,736,000 as of 31 January 2023.

Review of Cash Flow

The Group recorded net cash generated from operating activities of S\$322,000 in 9MFY2024, as compared to net cash used in operating activities of S\$1,012,000 in 9MFY2023. The increase was mainly attributable to favourable working capital change in inventories, and trade and other receivables, partly offset by unfavourable working capital change in contract liabilities.

The net cash flows used in investing activities of S\$4,000 in 9MFY2024 was due to purchase of plant and equipment.

The net cash flows used in financing activities of S\$648,000 in 9MFY2024 was mainly attributable to the repayment of lease liabilities and bank loan, partly offset by loan obtained during the period.

On account of the above, the Group's cash and cash equivalents in the consolidated statement of cashflows comprise cash and bank balances of S\$107,000 as of 31 October 2023.

26 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, the issuer must explain any variance between the forecast or prospect statement and the actual results

No forecast or prospect statement has been previously disclosed to shareholders.

27 Commentary at the date of the announcement of the competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

With global supply chains continuing to be disrupted and inflation rising, the Group anticipates slower economic growth in the coming quarters, which may adversely impact consumer sentiment. Nonetheless, the Group will continue to execute its cores strategies in developing new products, expanding into new sales channels and apply prudent cost management measures.

The Group notes that a sizable portion of NF's revenue is still generated by walk-in customers to its retail outlets. As COVID-19 has greatly increased the prevalence and acceptance of e-commerce, the Group will continue augmenting its online presence and platforms. The Group has also undertaken successful business-to-business ("B2B") collaborations and intends to continuously seek out other reputable partners in complementary industries.

Trading in the shares of the Company has been suspended since 1 April 2019. The Group has since resolved its previous regulatory irregularities and addressed other areas of concern which had contributed to its trading suspension. As such, the Company had, on 15 June 2023, announced that it had submitted a proposal for the resumption in the trading of its shares (the "ROTP Application") to the SGX RegCo. The ROTP Application is currently still under review by SGX RegCo and the Company has been engaging SGX RegCo regularly on the ROTP application. The Company will make further announcements as and when there are material developments in the ROTP Application.

The Company also announced on 14 June 2023 that it had, *inter alia*, entered into new investment agreements with several investors, which is intended to substantially replace the investment by Qiren Holdings Pte. Ltd. The proceeds from such new investment agreements are intended to

CAMSING HEALTHCARE LIMITED

provide the Group with much-needed financing for its business initiatives. Shareholders may refer to the Company's announcement dated 14 June 2023 for more details.

28 Dividend

(a) Current Financial Period Reported On

Any dividend recommended for the current financial period reported on?

No.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

No.

(c) Date Payable

Not applicable.

(d) Books Closure Date

Not applicable.

29 If no dividend has been declared/recommended, a statement to that effect

No dividend has been declared or recommended for the current financial period as the Company and/or the Group recorded net losses for the financial period under review.

30 If the Group has obtained a general mandate from shareholders for Interested Person Transactions ("IPTs"), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

During the financial period under review, the Group did not have a general mandate pursuant to Rule 920 of the SGX-ST Listing Manual. There were no Interested Person Transactions exceeding S\$100,000 in aggregate value for the current financial period.¹

¹ In arriving at the conclusion, the Board wishes to state for the record that it did not include the transactions with Caring Global Health Management (Beijing) Co., Ltd, Global Biotech Medical Inc., Limited, I-Nitra Consulting Limited as interested person transactions as RSM did not conclude these three companies as interested persons after their extensive investigation from April 2019 to September 2020. Please refer to the ES-SAR released by Company on 1 September 2020 via SGXNet.

CAMSING HEALTHCARE LIMITED

31 Report of persons occupying managerial positions who are related to a director, chief executive officer or substantial shareholder Pursuant to Rule 704 (13)

The Board confirms that, to the best of its knowledge, as of the date hereof, none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a Director, Chief Executive Officer or Substantial Shareholder of the Company.

32 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1).

Pursuant to Rule 720(1) of the Listing Manual, the Company has procured undertakings from all its directors and executive officers.

33 Negative confirmation by the Board pursuant to Rule 705(5)

On behalf of the board of directors of the Company, we hereby confirm to the best of our knowledge that nothing has come to the attention of the Board which may render the unaudited financial statements and dividend announcement for the nine months ended 31 October 2023 to be false or misleading in any material aspect.

BY ORDER OF THE BOARD

YEO CHOON TAT
Executive Director
15 December 2023